Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in General Community: a Single-Center Experience

Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a novel drug which has shown significant efficacy and survival benefit for treatment of various B-cell malignancies.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Naveed Ali, Syed Imran Mustafa Jafri, Faizan Malik, Mark Sundermeyer, Peter Pickens Source Type: research